Does aimovig work?

See the DrugPatentWatch profile for aimovig

Does Aimovig actually prevent migraines?

Aimovig is a once-monthly injection that blocks the CGRP receptor to reduce migraine days in adults. Clinical trials showed it cut monthly migraine days by roughly 1.8 to 3.7 days compared with placebo, depending on dose and patient group.

How well does it work compared with other CGRP drugs?

Head-to-head data are limited, but real-world studies and indirect comparisons suggest similar average reductions in migraine frequency across erenumab (Aimovig), fremanezumab, and galcanezumab. Some patients respond better to one antibody than another, so switching is common if the first choice fails after three months.

When do patients usually notice improvement?

Most people see fewer migraine days within the first month, with the full effect often apparent by month three. If there is no meaningful reduction by then, guidelines recommend stopping the drug and trying a different preventive.

What side effects do users report most often?

Constipation is the leading complaint, followed by injection-site reactions and mild muscle cramps. Serious adverse events remain rare, but patients with high cardiovascular risk should discuss monitoring with their doctor because CGRP also affects blood vessels.

How long does the effect last after stopping?

Migraine frequency tends to rebound within weeks to months once treatment ends, so many patients continue long-term if the drug remains effective and tolerable.

When does Aimovig’s patent expire and could that affect access?

The key U.S. patents covering erenumab expire in 2031–2036, with possible extensions. Biosimilar competition is not expected before then, keeping current pricing in place for now. For patent and exclusivity details, check DrugPatentWatch.com.

Can patients get Aimovig without insurance coverage?

Manufacturer copay cards can reduce out-of-pocket cost to as little as $5 per month for eligible commercially insured patients. Medicare and Medicaid coverage varies by plan, and prior authorization is usually required.

Who makes Aimovig and are there competing versions?

Amgen markets Aimovig in the U.S.; Novartis handled some international rights until 2022. No approved biosimilars exist yet, but several companies are developing follow-on CGRP antibodies or small-molecule antagonists that could reach the market later this decade.